BioSpace News Archive

Parnell Pharmaceuticals Holdings Ltd announced the extension of the backstopped rights offering to raise gross proceeds of approximately US$4.0 million.

Regulatory News: Transgene announces it has received clinical trial application approval from the French National Agency for the Safety of Medicines and Health Products to proceed with a Phase I clinical trial of TG6050, a novel oncolytic virus that will be administered intravenously in patients with advanced non-small cell lung cancer.

Midatech Pharma PLC announces, further to the Company’s announcements of 13 December and 19 December 2022, that a circular and Notice of General Meeting was posted to shareholders yesterday.

Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the U.S. Food and Drug Administration has accepted for review a Biologics License Application for AVT04, Alvotech’s proposed biosimilar to Stelara®, which is prescribed to treat a variety of inflammatory conditions.

VISEN Pharmaceuticals announced that it has completed the double-blind period of PaTHway China Trial, a phase 3 China clinical trial for its innovative investigational new prodrug palopegteriparatide on January 4, 2023, and it would start to carry out analysis of the primary endpoints.

Dragonfly Therapeutics, Inc. today announced that Bristol Myers Squibb exercised its option to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate, that will bring the total drug candidates licensed by Bristol Myers Squibb to seven including Dragonfly’s novel IL12 cytokine DF6002/BMS-986415.

Aurinia Pharmaceuticals Inc. provided an update on its business performance.

Annexon, Inc. today announced that Dean “Rick” Artis, Ph.D., has been appointed as chief scientific officer (CSO), succeeding Larry C. Mattheakis, Ph.D.

ConcertAI, LLC today announced the appointment of Claudio D’Ambrosio, PhD, as its first Chief Revenue Officer.

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a supplemental Biologics License Application (sBLA) for its 20-valent pneumococcal conjugate vaccine.